Status and phase
Conditions
Treatments
About
A single arm pilot study conducted to assess the feasibility of having Manitoba Pharmacists provide support (product and cognitive) to low-income (receiving social assistance) smokers wishing to quit smoking.
Full description
SYNOPSIS - Manitoba Pharmacist Initiated Smoking Cessation Program Overview Background The Manitoba government supports the role of the pharmacist as an integral part of the primary health care team delivering quality care and service to Manitobans. The role of the Pharmacist is ever evolving and expanding to meet the needs of their clients including comprehensive medication therapy management and expanded preventative expert. Community pharmacists are one of the most accessible health care professionals and provide a wide range of clinical services in the neighborhoods, towns, and cities across this province.
As part of the Manitoba government's wellness initiative, the government is strategically committed towards reducing the use of tobacco through public policy. Smoking is one of the leading causes of death in Manitoba and the use of tobacco is responsible for more than 50% of lung, respiratory, and oral cancers and a substantial factor in cardiovascular disease. While decreases in smoking rates have been achieved in recent years, Manitoba continues to exceed the national average of 17.3%, ranking the province with the third highest smoking prevalence. Manitoba' current smoking rates warrant continued efforts to reduce smoking in youth and adults.
While many believe smoking to be lifestyle choice it is also known to be a changeable lifestyle behavior and a significant determinant of health. It is also known to be a serious addiction that is very difficult to overcome both physically and emotionally. As part of Manitoba's targeted approach to smoking cessation, a partnership has been forged to develop and implement the pilot program: Manitoba Pharmacist Initiated Smoking Cessation Program.
Methodology The role of the pharmacist can best be described as underutilized and often an under recognized resource in smoking cessation programs. For individuals who smoke, many find smoking cessation overwhelming and difficult without assistance, including smoking cessation drugs and ongoing support and counselling. Many pharmacists have received additional knowledge and training specifically for initiating and monitoring a smoking cessation for individual clients. The Manitoba Pharmacist Smoking Cessation Program will provide access for 100 clients to the vital components necessary to quit smoking. Lower socioeconomic status is associated with higher rates of smoking. The Manitoba Employment and Income Assistance program provides support for lower income individuals in Manitoba. This smoking cessation program is a controlled pilot study providing clients with the most appropriate smoking cessation drugs along with the benefit of one to one pharmacist support and counselling.
Smoking Cessation Program Objectives
The following are the program objectives:
Program Scope A. Target Population
B. Participation Provider (Pharmacy and pharmacist)
Client Participation
iii. After consent has been obtained the patient will be provided with some forms to complete to assess their current smoking patterns and readiness to quit. When the completed forms are returned an initial assessment interview will be booked with the pharmacist.
iv. During the initial assessment interview:
The pharmacist will assess the level of dependence from the completed Fagerstrom Tolerance Scale and assess the motivations for smoking from the Why Test.
Potential drug interactions between medications and smoking/smoking cessation will be assessed.
The participant will be introduced to the Smoking Cessation Form and asked to record the symptoms, triggers, cessation product use and side effects on a daily basis.
The participant will be provided with a variety of educational materials to help guide their individualized quit plan (How Do I Want to Quit?, Why Do I Want to Quit?, When Do I Want To Quit?)
The pharmacist will work with the participant to complete the Pre-Quit Planning form
Additional Educational materials may be provided as needed ( Count Down to Quit Date, Breaking the Cycle of Addiction Date, My Reasons to Quit Smoking, Enlisting Support) v. Quit Day Visit:
The pharmacist will work with the participant to complete the Quit Day Plan. 2. The participant will be provided with the Quit Diary to record smoking 3. Additional Educational materials will be provided as needed (Managing Withdrawal Symptoms, Minimizing Weight Gain, Dealing with the Urge to Smoke, Managing Slips and Relapse, List of Resources).
Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups.
vi. Phone Follow-up - 1 Week Post Quit
The pharmacist will provide telephone follow-up and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
They will complete the Smoking Cessation Assessment Form with the patient. vii. 1 Month Post Quit Visit
The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
They will complete the Smoking Cessation Assessment Form with the patient. viii. 3 Month Quit Visit
The pharmacist will meet with the participant and review what has worked well and any challenges with withdrawal they have experienced. The Quit Plan will be modified as needed.
They will complete the Smoking Cessation Assessment Form with the patient.
Ensure the participant has a copy of the Smoking Cessation Assessment From for future telephone follow-ups.
ix. Phone Follow-up - 6 Month Post Quit
C. Program Duration Total duration of the study will be a 6-15 months. The participant will have access to smoking cessation pharmacy counseling services and smoking cessation products for a period of three months from the initiation in the pilot project. The intervention component of the pilot project will be available between January and April 2015.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
119 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal